礼来公司的药物在患有脱发和湿疹改善的青少年中显示出强烈的头发再生，FDA 正在等待提交。 Eli Lilly's drugs show strong hair regrowth in teens with alopecia and improved eczema, with FDA submission pending.

艾利利利公司报告了巴里西丁和勒布里奇祖马布的第三期试验结果,显示严重脱发区域的青少年有显著的头发再生,中度至严重湿疹患者的症状持续改善. Eli Lilly reported positive Phase 3 trial results for baricitinib and lebrikizumab, showing significant hair regrowth in adolescents with severe alopecia areata and sustained symptom improvement in patients with moderate-to-severe eczema. 在一次对257名青少年的试验中,4毫克的巴里西提尼b导致头皮发成功重新生长71%,一年后几乎完全恢复41.2%,没有新的安全关切。 In a trial of 257 adolescents, 4 mg of baricitinib led to successful scalp hair regrowth in 71% and near-complete regrowth in 41.2% after one year, with no new safety concerns. 另一项试验显示,每四到八周服用一次,勒布里奇祖马布有效改善了湿疹症状. A separate trial showed lebrikizumab effectively improved eczema symptoms with dosing every four or eight weeks. 该公司已向FDA提交了潜在标签扩展的数据. The company has submitted data to the FDA for potential label expansions.